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Recruitment of Dok-R to the EGF receptor through its PTB
domain is required for attenuation of Erk MAP kinase activation
Nina Jones and Daniel J. Dumont
Dok (for downstream of tyrosine kinases) proteins are a
newly identified family of docking molecules that are
characterized by the presence of an amino-terminal
pleckstrin homology (PH) domain, a central putative
phosphotyrosine-binding (PTB) domain and numerous
potential sites of tyrosine phosphorylation [1–6]. Here,
we explore the potential role of the Dok family member
Dok-R (also known as p56Dok2 or FRIP) in signaling
pathways mediated by the epidermal growth factor
(EGF) receptor. An intact PTB domain in Dok-R was
critical for its association with two PTB-binding
consensus sites on the EGF receptor and the PH
domain further contributed to stable in vivo binding and
tyrosine phosphorylation of Dok-R. Multiple sites on
Dok-R were tyrosine-phosphorylated following EGF
stimulation; phosphorylated Tyr276 and Tyr304 are
proposed to dock the tandem Src homology 2 (SH2)
domains of the p21Ras GTPase-activating protein
rasGAP and Tyr351 mediates an association with the
SH2 domain of the adapter protein Nck. Interestingly,
we have found that Dok-R could attenuate EGF-
stimulated mitogen-activated protein (MAP) kinase
activation independently of its association with rasGAP.
Together, these results suggest that Dok-R has an
important role downstream of growth factor receptors
as a potential negative regulator of signal transduction. 
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Results and discussion
Tyrosine phosphorylation of Dok in response to EGF
stimulation has previously been reported [7,8]. Given the
similar expression profiles of Dok and Dok-R, we rea-
soned that Dok-R might also function in EGF-mediated
signaling pathways. To test this, we used the COS1 cell
line, which expresses high levels of EGF receptor [9] and
does not contain endogenous Dok-R (data not shown);
there is thus no interference with the analysis of signaling
mediated by exogenously expressed forms. In COS1 cells
transiently expressing full-length Dok-R, we found that
EGF stimulation resulted in complex formation between
the EGF receptor and Dok-R and in tyrosine phosphoryl-
ation of both proteins (see Supplementary material). A
region of Dok-R similar to the PTB domain of insulin
receptor substrate-1 (IRS-1) has previously been shown to
mediate binding of Dok-R to the phosphorylated Tek/Tie2
receptor [3]. As the sequence similarity between PTB
domains is limited and as the Tek/Tie2 receptor does not
contain the consensus binding site for PTB domains, we
wanted to ascertain whether this region of Dok-R repre-
sented a true PTB domain. Purified fusion proteins of glu-
tathione-S-transferase (GST) with the putative Dok-R
PTB domain (GST–PTB) or a mutant domain lacking two
conserved arginine residues (GST–PTB*) [10,11] were
used to precipitate the EGF receptor from lysates of non-
transfected unstimulated or EGF-stimulated COS1 cells.
Figure 1a shows that the PTB domain of Dok-R could
precipitate the EGF receptor following EGF stimulation
and that the PTB* domain could not.
To determine which tyrosines of the EGF receptor could
mediate the interaction with Dok-R, we designed a series
of synthetic peptides corresponding to the sequences sur-
rounding the autophosphorylation sites of the EGF recep-
tor (Figure 1b) [12] and mixed them in vitro with purified
GST–PTB fusion proteins. The GST–PTB domain of
Dok-R could be precipitated by phosphopeptides repre-
senting Tyr1086 (pY1086) and Tyr1148 (pY1148) but not
by the unphosphorylated counterparts (Y1086 and Y1148;
Figure 1c). In contrast, neither GST–PTB* nor GST
alone could be precipitated by either of these phospho-
peptides and the PTB domain of Shc (GST–Shc) associ-
ated almost exclusively with pY1148 (Figure 1c). Tyr1086
and Tyr1148 are found within the predicted autophos-
phorylated Asn-Pro-X-Tyr (NPXY in the single-letter
amino acid code, where X is any amino acid), so to investi-
gate the contribution of the asparagine and proline
residues in target binding, we designed synthetic phos-
phopeptides in which either of these residues was
mutated to alanine. Mutation of either of these residues
resulted in abrogation of the interactions, although weak
binding to phosphopeptides lacking the proline residues
(pY1086PA and pY1148PA) could still be seen in longer
exposures of the immunoblot  (Figure 1c). Estimates of
the dissociation constants (Kd) between pY1086 and
pY1148 phosphopeptides and the soluble PTB domain of
Dok-R revealed that the PTB domain could bind to both
phosphopeptides with similar relative affinities (Table 1).
Our results to this point have demonstrated that the PTB
domain of Dok-R is required for binding of Dok-R to the
phosphorylated EGF receptor in vitro. As Dok-R also con-
tains a PH domain, however, we wanted to examine the
contribution of each domain to the association in vivo. We
therefore generated a series of mutations in full-length
Dok-R that would disrupt the functions of the individual
domains, introduced the mutants into COS1 cells and
examined their ability to associate with the EGF receptor
and undergo tyrosine phosphorylation in response to
EGF. Disruption of the PTB domain (PTB*) appeared to
have a more dramatic effect on EGF receptor binding and
Dok-R phosphorylation than deletion of the PH domain
(∆PH), although the disruption of both domains com-
pletely abrogated Dok-R phosphorylation (PTB*/∆PH)
(Figure 2). Phosphorylation of Dok-R has previously been
shown to establish docking sites for downstream SH2-
domain-containing signaling proteins including rasGAP
and Nck [3–5]. We found that rasGAP and Nck could
associate with Dok-R following EGF stimulation and that
phosphorylation at both Tyr276 and Tyr304 was required
for rasGAP binding whereas Tyr351 was required for Nck
binding (see Supplementary material). These results are
in agreement with those recently reported by Lock et al.
[6], who showed that independent tyrosine residues
mediate the interactions of rasGAP and Nck with Dok-R. 
Recruitment of Dok-R to the EGF receptor and its associa-
tion with rasGAP suggested that signaling through Dok-R
might negatively regulate the Ras–MAP kinase pathway.
To test this, we examined the effect of Dok-R expression
on activation of the MAP kinase extracellular-signal-regu-
lated kinase 2 (Erk2) by immunoblotting with phospho-
specific anti-Erk antibodies and in vitro phosphorylation of
the substrate myelin basic protein (MBP). Expression of
wild-type Dok-R in COS1 cells resulted in a marked
reduction in phosphorylation of Erk2 following EGF stim-
ulation when compared with cells expressing the vector
control (Figure 3a). Interestingly, this suppression of Erk2
activation was not abrogated by the mutant that cannot
bind rasGAP (DM; Figure 3a) or a mutant  that cannot
bind rasGAP or Nck (data not shown). As expected, the
PTB*/∆PH mutant did not reduce Erk2 phosphorylation
(data not shown). 
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Figure 1
Dok-R contains a functional PTB domain that
mediates the association with two NPXY
motifs of the EGF receptor. (a) Lysates from
unstimulated (–) or EGF-stimulated (+) COS1
cells were incubated with immobilized GST,
Dok-R GST–PTB or Dok-R GST–PTB*.
Bound proteins were detected with anti-EGF
receptor antibodies (Blot). EGF receptor
could be detected in both unstimulated and
EGF-stimulated non-precipitated lysates
(lysate). (b) Schematic representation of the
intracellular domain of the EGF receptor
showing three tyrosine autophosphorylation
sites (Tyr1086, Tyr1148 and Tyr1173) and
one non-phosphorylated site (Tyr1114). The
remaining autophosphorylation sites (Tyr992
and Tyr1068) were not studied here. The
synthetic biotinylated peptides corresponding
to these sites that were used in the mapping
studies are shown with the asparagine, proline
and tyrosine residues that were altered in
similar peptides in bold. (c) Associations
between the various EGF receptor peptides
and purified GST-fusion proteins were
allowed to form in vitro and resultant
complexes were recovered using
streptavidin–agarose beads. Bound fusion
proteins were visualized with anti-GST
antibodies. The lower two panels show
different exposures of the same immunoblot.
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Table 1
Relative affinities of the PTB domain of Dok-R for phospho-
peptides representing EGF receptor Tyr1086 and Tyr1148.
EGF receptor phosphopeptide Binding constant (Kd)
Tyr1086 132 nM
Tyr1148 117 nM
The PTB domain of Dok-R binds EGF receptor phosphopeptides with
similar relative affinities. Phosphopeptides representing Tyr1086 and
Tyr1148 were immobilized on sensor chips and the dissociation
constants (Kd) between each of these phosphopeptides and the
soluble PTB domain of Dok-R were determined using real-time
biosensor (BIAcore) analysis [15]. This analysis provides an estimate
of the relative affinity of the PTB domain for each of the two
phosphopeptides. These values are likely to be overestimates because
of the dimeric nature of GST in these experiments [16].
The degree of Erk2-mediated phosphorylation of MBP
mirrored the observed attenuation of Erk2 phosphoryla-
tion (Figure 3a). Quantitation of the levels of MBP phos-
phorylation revealed that, in cells expressing the vector
control, phosphorylation of Erk2 was induced within
2 minutes following EGF stimulation and persisted for at
least 10 minutes (Figure 3b). In contrast, in cells express-
ing wild-type Dok-R, there was 10-fold less induction of
Erk2 following 2 minutes of EGF stimulation and the
level of activation did not reach vector control levels after
10 minutes of stimulation (Figure 3b). Interestingly, cells
expressing the DM mutant induced Erk2 only marginally
more than wild-type Dok-R, suggesting that the associa-
tion between Dok-R and rasGAP is not required for this
attenuation of Erk activity.
As the PTB domain of Dok-R can associate in vitro with
the same phosphorylated tyrosine residue on the EGF
receptor as Shc, we wanted to confirm that attenuation of
Erk activation as a result of Dok-R expression was not due
to displacement of Shc from the EGF receptor by Dok-R.
We thus isolated Shc from unstimulated or EGF-stimu-
lated COS1 cells that were either untransfected or trans-
fected with Dok-R. Immunoprecipitated Shc isoforms
became tyrosine-phosphorylated to the same extent with
or without Dok-R; activated EGF receptor and Grb2 were
readily detectable in these immunoprecipitates (Figure 4).
Tyrosine phosphorylation of Dok-R and the associated
EGF receptor could also be observed, and Dok-R did not
associate with Grb2 (Figure 4). These experiments
demonstrate that Shc signaling complexes are unaffected
by the expression of Dok-R and the attenuation of Erk
activation by Dok-R was not simply due to a loss of
recruitment of the Shc–Grb2 complex to the receptor.
Our findings are consistent with those of Nelms et al. [4],
which demonstrate that overexpression of FRIP in 32D
cells inhibits the activation of MAP kinase following inter-
leukin 2 stimulation. As rasGAP negative regulates Ras [13],
the binding of rasGAP to Dok-R is an attractive mechanism
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Figure 2
The PTB domain of Dok-R is required for binding to the EGF receptor
in vivo and for tyrosine phosphorylation. Full-length wild-type Dok-R
(WT) or mutant forms of Dok-R containing inactivating mutations in the
PTB domain (PTB*), a deletion of the entire PH domain (∆PH) or both
mutations (PTB*/∆PH) were introduced into COS1 cells. Unstimulated
or EGF-stimulated lysates from these cells were immunoprecipitated
(IP) with anti-Dok-R antibodies and immunoblotted with anti-phospho-
tyrosine (pY) antibodies. Immunoblotting with anti-Dok-R antibodies
shows approximately equal expression of all Dok-R mutants and no
expression of Dok-R is detected in cells expressing the vector alone.
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Figure 3
Dok-R expression attenuates EGF-induced Erk2 activation
independently of rasGAP. (a) GST-tagged Erk2 (0.1 µg of plasmid) was
coexpressed in COS1 cells with wild-type or mutant Dok-R (10 µg) and
cells were left unstimulated or stimulated with EGF for the indicated
time. Lysates were precipitated (Ppt) with glutathione–sepharose and
subjected to an in vitro kinase assay using MBP as substrate. Samples
were analyzed by SDS–PAGE and autoradiography or immunoblotting
with anti-phospho-Erk2 antibodies. The immunoblot was reprobed with
anti-GST antibodies to show approximately equal expression of Erk2 in
all lanes. Non-immunoprecipitated lysates were immunoblotted with anti-
HA antibodies to demonstrate equal expression of Dok-R mutants.
(b) The MBP kinase activity assay was quantitated by phosphorimager
analysis using the ImageQuaNT program (Molecular Dynamics); levels
of MBP phosphorylation were normalized for relative expression of both
Erk2 and Dok-R. Data shown are representative of a single experiment,
which has been independently reproduced several times. 
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for suppression of Erk activation by Dok-R. Both Dok and
Dok-R can bind rasGAP, but overexpression of Dok has no
effect on MAP kinase activation in response to insulin [14],
and a mutant of Dok-R that could not bind rasGAP was
unable to rescue Erk activation levels in our studies. These
observations suggest that the functional differences in MAP
kinase activation between Dok and Dok-R are probably due
to unidentified binding partners that are not conserved
between the two Dok family members and the physiologi-
cal consequence of rasGAP binding remains to be deter-
mined. The identification of additional Dok-family
signaling partners will further illuminate the divergent func-
tions of these docking proteins in growth factor signaling.
Supplementary material
Supplementary material showing the association of Dok-R with rasGAP
and Nck and additional methodological details is available at
http://current-biology.com/supmat/supmatin.htm.
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Figure 4
Shc signaling is not impaired in cells expressing Dok-R. COS1 cells
were transfected (TF) with wild-type Dok-R or the control vector,
stimulated with EGF (+) or left unstimulated (–), immunoprecipitated
(IP) with anti-Dok-R or anti-Shc antibodies and immunoblotted with
anti-phosphotyrosine (pY) antibodies. The immunoblot was
subsequently reprobed with anti-EGF receptor, anti-Shc and anti-Grb2
antibodies and non-immunoprecipitated lysates (lysate) indicate the
position of all proteins.
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Results
Dok-R can associate with rasGAP and Nck through Tyr276,
Tyr304 and Tyr351 following EGF stimulation
In this report, we have examined the ability of Dok-R to
associate with the EGF receptor. In COS1 cells transiently
expressing Dok-R, co-immunoprecipitation of Dok-R and
EGF receptor and tyrosine phosphorylation of Dok-R
could be observed following EGF stimulation (Figure S1).
This phosphorylation established docking sites for the
SH2-domain-containing signaling proteins rasGAP and
Nck (Figure S2a). The consensus binding motif for both
rasGAP and Nck is Tyr–X–X–Pro (YXXP) [S1–S3]; this
motif is found four times in the Dok-R amino acid
sequence at Tyr194, Tyr276, Tyr304 and Tyr351. Syn-
thetic phosphopeptides corresponding to the last three
YXXP motifs were generated; the amino-terminal SH2
domain of rasGAP (GAP-N) was found to associate with
all three YXXP phosphopeptides in vitro, whereas the SH2
domain of Nck could associate only with phosphopeptides
corresponding to Tyr304 and Tyr351 (Figure S2b). The
presence of a putative Grb2-binding site was also
observed in the extreme carboxy-terminal region of Dok-
R (Tyr402), but we did not observe any association
between the SH2 domain of Grb2 and a phosphopeptide
corresponding to this tyrosine (Figure S2b). 
The tyrosine residues on Dok-R that are phosphorylated
in response to growth factor stimulation have not been
defined, so the phosphopeptide analysis represented an
initial approach to define the binding sites of rasGAP and
Nck on Dok-R. To determine which sites could become
tyrosine phosphorylated upon EGF stimulation in vivo, we
generated HA-tagged tyrosine to phenylalanine point
mutations in full-length Dok-R at Tyr276 (Y276F),
Tyr304 (Y304F) and Tyr351 (Y351F). We also generated
compound mutations in which Tyr276 and Tyr304 were
doubly mutated (DM) or all three tyrosine residues were
mutated (TM). All mutants were expressed at levels
equivalent to wild-type Dok-R in COS1 cells and upon
EGF stimulation, all mutants displayed similar levels of
tyrosine phosphorylation and association  with the EGF
receptor (Figure S2c). Because the triple mutant appeared
to be phosphorylated to the same extent as wild-type
Dok-R, it is likely that there are additional sites of tyro-
sine phosphorylation throughout the protein. 
Lysates from these cells were then incubated with immo-
bilized GST–SH2 domains of rasGAP and Nck and bound
proteins were visualized by anti-HA immunoblotting.
Both the amino-terminal (GAP-N) and the tandem
SH2–SH3–SH2 (GAP–NC) domains of rasGAP associated
with all three single point mutants (Figure S2c), confirm-
ing the peptide data that showed that rasGAP can bind
more than one site on Dok-R. The compound double
mutant that lacks both Tyr276 and Tyr304 was no longer
able to interact with the SH2 domains of rasGAP,
however (Figure S2c), suggesting that rasGAP associates
with Dok-R through a bisphosphorylated target motif
comprising Tyr276 and Tyr304. The SH2 domain of Nck
could associate with a phosphopeptide representing tyro-
sine residue 304, but mutation of this site in full-length
Dok-R had no effect on Nck binding (Figure S2c). In con-
trast, mutation of Tyr351 in full-length Dok-R completely
abrogated binding of Nck to Dok-R (Figure S2c), suggest-
ing that Nck interacted with Dok-R exclusively through
Supplementary material
Figure S1
Dok-R is a novel substrate of the EGF receptor. Lysates from
unstimulated (–) or EGF-stimulated (+) COS1 cells transiently
expressing full-length Dok-R were immunoprecipitated (IP) with anti-
EGF receptor or anti-Dok-R antibodies and immunoblotted as
indicated. Non-immunoprecipitated lysates (lysate) show equal
amounts of EGF receptor and Dok-R in the initial lysates.
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this phosphorylation site. These predictions were con-
firmed when the compound mutations were analyzed, as
the DM mutant was still able to bind Nck but the TM
mutant could no longer associate with Nck (Figure S2c).
In vivo, Nck was coimmunoprecipitated with Y276F,
Y304F and DM but not with Y351F or TM (Figure S2d).
In summary, these results demonstrate that upon EGF
stimulation, Tyr276, Tyr304 and Tyr351 of Dok-R are
phosphorylated — 276 and 304 are required for rasGAP
binding and Tyr351 is required for Nck binding. 
The SH2 domain of Nck appears to bind exclusively to
phosphorylated Tyr351 of Dok-R, which conforms to the
predicted YDEP optimal binding motif for Nck [S1]. This
tyrosine residue also represents a putative rasGAP-binding
site, but the SH2 domains of rasGAP do not appear to bind
this site in the context of full-length Dok-R. They associate
instead with two different phosphorylated YXXP motifs at
Tyr276 and Tyr304. The SH2 domains of rasGAP have
been shown to bind simultaneously to two closely spaced
phosphotyrosine residues in p190 rhoGAP that are both
contained within the motif YXXPXD [S3]. This extended
motif is conserved in Dok-R at Tyr276 and Tyr304 and
mutagenesis of these closely linked tyrosine residues in
Dok-R completely abrogates the interaction between
rasGAP and Dok-R. The simultaneous interaction of both
SH2 domains with bisphosphorylated targets is thought to
promote a conformational change in rasGAP that exposes
the target binding surface of the SH3 domain [S3]. We
speculate that a similar mechanism occurs upon interaction
of rasGAP with Dok-R following EGF stimulation.
Recently, the Nck protein has been shown to exist as
Nckα/Nck1 and Nckβ/Nck2 isoforms [S4,S5]. Although
neither isoform could interact directly with the EGF
receptor, the Nckβ isoform was shown to associate with
Dok more strongly than the α isoform [S4]. Furthermore,
the β isoform was shown to inhibit EGF-stimulated DNA
synthesis in an SH2-domain-dependent manner [S4].
Although we did not determine the identity of the Nck
isoform in our immunoprecipitates because of antibody
limitations, it is interesting to speculate that the effect of
Dok-R expression on Erk activation may in fact be medi-
ated by Nckβ. This notwithstanding, the inability of the
mutant that cannot bind rasGAP or Nck to rescue Erk
activation levels suggests that additional effector mole-
cules are involved in this downregulation. 
Supplementary materials and methods
Plasmids
The cDNA encoding full-length Dok-R [S6] was subcloned into
pcDNA3.1(+) (Invitrogen) or pcDNA3.1(+) containing a hemagglutinin
(HA) tag (HA-pcDNA3.1; a kind gift of Bryan Snow, AMGEN Institute,
Toronto, Canada). Point mutations were introduced using the
QuikChange site-directed mutagenesis kit (Stratagene) and all muta-
tions were confirmed by sequencing. To generate Dok-RPTB* and Dok-
R GST–PTB*, Arg202 and Arg217 were altered to glutamine.
Dok-R∆PH (amino acids 142–412) was constructed using PCR with
appropriate primers containing restriction sites suitable for in-frame
insertion into HA-pcDNA3.1. The Dok-R GST–PTB construct was
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Figure S2
Dok-R functions as a docking molecule for
SH2-domain-containing proteins through
phosphorylation at Tyr276, Tyr304 and
Tyr351. (a) Lysates from unstimulated or
EGF-stimulated COS1 cells expressing full-
length wild-type Dok-R were immuno-
precipitated with anti-Dok-R antibodies. Non-
immunoprecipitated lysates (lysate) show the
expression levels of rasGAP and Nck. (b) The
position of three tyrosine residues found
within YXXP motifs in the carboxy-terminal
region of Dok-R (276, 304, 351) as well as
one YXNX motif (402) are shown. Phospho-
peptides were used for in vitro mixing
experiments as described in Figure 1c and the
results are presented with relative binding
indicated as + or –. Interactions that were not
determined are denoted ND. (c) Tyrosine to
phenylalanine mutations were introduced in
full-length HA-tagged Dok-R at the three
indicated YXXP motifs and mutants were
expressed in COS1 cells and stimulated with
EGF. DM harbors mutations at both Tyr276
and Tyr304; TM has mutations at all three
sites. Lysates from these cells were incubated
with immobilized GST–SH2 fusion proteins
and bound proteins were visualized by anti-
HA immunoblotting. (d) Lysates from these
cells were also immunoprecipitated with anti-
Dok-R antibodies followed by anti-Nck
immunoblotting to confirm the in vivo binding
of Nck to Tyr351.
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described previously [S6] and pEBG-Erk2 was a gift of Jim Woodgett
(Ontario Cancer Institute, Toronto, Canada).
Cell culture, transient transfection and binding assays
COS1 cells were maintained and processed as described in [S6]
except that cells were serum-starved for 24 h in DMEM containing
0.1% fetal bovine serum (Gibco BRL) before stimulation with
100 ng/ml EGF (Upstate Biotechnology). MBP phosphorylation assays
were performed essentially as described in [S7].
GST fusion proteins and antibodies
Production of GST fusion proteins has been described in [S6]. The
SH2-SH3-SH2 domain fusion protein of rasGAP was purchased from
Santa Cruz. Peptide association assays are described in [S8] and the
sequences corresponding to the phosphorylated Dok-R peptides are as
follows: Y276, RPESPpYSRPHDSL; Y304, APEGEpYAVPFDTV; Y351,
DHIpYDEPEGVA; Y402, PQATEpYDNVILKK. Affinity-purified polyclonal
anti-Dok-R antibodies have been described previously [S6]. Polyclonal
anti-Shc antibodies were a gift of Jane McGlade (Hospital for Sick Chil-
dren, Toronto, Canada). Monoclonal anti-EGF receptor antibodies
(E12020, Transduction Labs) in conjunction with rabbit anti-mouse IgG
(Upstate Biotechnology) were used for immunoprecipitation and poly-
clonal anti-EGF receptor antibodies (1005; Santa Cruz) were used for
western blotting. Monoclonal anti-HA clone 12CA5 (Boehringer
Mannheim) was used in immunoprecipitations and as a horseradish per-
oxidase conjugate for western blotting. The remaining antibodies used
for western blotting were obtained as follows: monoclonal anti-phospho-
tyrosine 4G10 (Upstate Biotechnology); monoclonal anti-Grb2, anti-
rasGAP and anti-Nck (G16720, G12920 and N15920, Transduction
Laboratories); monoclonal phospho-MAP kinase p44/p42 (E10, New
England Biolabs); and polyclonal anti-GST (Z-5, Santa Cruz).
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